Multicenter, three-arm, double-blind, double-blind, parallel-group, placebo-controlled study for the evaluation of the efficacy and safety of the extended-release formulation of betahistine PR 48 mg once daily compared to the formulation of Conventional release of betahistine IR 24 mg, twice daily in the treatment of adult patients with Meniere's disease. BERTIGO